Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Imaging in Progressive Supranuclear Palsy
NCT02605785Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2015
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of flortaucipir in progressive supranuclear palsy (PSP), sponsored by Mayo Clinic. Primary endpoint: Amount of Tau protein in the brain at 5 years. Started Nov 2015; status: recruiting.
02
Drugs
flortaucipir
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02605785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605785.